Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Achieve Life Sciences ( (ACHV) ) just unveiled an announcement.
On September 5, 2025, Achieve Life Sciences announced the resignation of Dr. Cindy Jacobs from her roles as Chief Medical Officer and President, effective October 6, 2025. The company is negotiating a consulting agreement with Dr. Jacobs to continue her advisory services, indicating a strategic shift in leadership while maintaining her expertise.
The most recent analyst rating on (ACHV) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page.
Spark’s Take on ACHV Stock
According to Spark, TipRanks’ AI Analyst, ACHV is a Underperform.
Achieve Life Sciences is navigating typical early-stage biotech challenges, including zero revenue and significant financial losses. While there are promising developments such as the upcoming NDA submission and strong clinical trial progress, these are offset by high operating expenses and dependency on future financing and regulatory approvals. Technical indicators reflect a downward trend, and the valuation remains unattractive with a negative P/E ratio.
To see Spark’s full report on ACHV stock, click here.
More about Achieve Life Sciences
Average Trading Volume: 1,320,680
Technical Sentiment Signal: Sell
Current Market Cap: $167.6M
Learn more about ACHV stock on TipRanks’ Stock Analysis page.